Swainsonine (Synthetic)
Product Code
TRC-S885000
CAS Number
Product Format
Neat
Molecular Formula
C8 H15 N O3
Molecular Weight
173.21
Product Categories
Alkaloids, TRC, Enzyme inhibitors, Additional Cancer Bioactive Molecules, Additional Neuro Products
Purity
>95% (HPLC)
Documentation
Looking for another lot?
To view all certificates of analysis immediately, please login to your account
or
{{ errors.first('lotNumber') }}
{{ errors.first('requestEmail') }}
For information about our data processing activities, please visit our Privacy Notice.
Enter your email address and we'll email you the relevant CoA for lots:
{{ coaPopupData.packSize.coaSelectedLotNumbers }}
{{ errors.first('coaEmail') }}
We will be sending the CoA to your email address {{ coaEmailPopupData.userEmail }}
Your request has been sent to our sales team to process.
Find an SDS for your region
{{ errors.first('selectedRegion') }}
{{ errors.first('sdsEmail') }}
For information about our data processing activities, please visit our Privacy Notice.
Your request has been sent to our sales team to process.
Product Information
Chemical Data
Analyte Name
Swainsonine
CAS Number
72741-87-8
Molecular Formula
C8 H15 N O3
Molecular Weight
173.21
Accurate Mass
173.1052
SMILES
O[C@@H]1CCCN2C[C@@H](O)[C@@H](O)[C@@H]12
InChI
InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1
IUPAC
(1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol
Product Data
Storage Temperature
-20°C
Shipping Temperature
Room Temperature
Country of Origin
CANADA
Product Format
Neat
Purity
>95% (HPLC)
Product Description
Swainsonine is a plant alkaloid derived from Swainsona canescens (a leguminous plant). It is a reversible, active-site directed inhibitor of a-mannosidase at concentrations of 5-10mM. At acid pH, swainsonine resembles an intermediate in the hydrolysis of mannosidases.Swainsonine completely inhibits mammalian Golgi a-mannosidase II (a-3/6-mannosidase in the glycoprotein processing pathway) and mammalian lysosomal a-mannosidase (acid mannosidase). At higher concentrations, swainsonine also inhibits mammalian cytosolic a-mannosidase. It has been shown to inhibit growth of transformed fibroblasts in soft agar and to enhance the antiproliferative effects of INF on murine lymphoreticular tumor cells in vitro. It also blocks the expression of b1-6 branched complex-type oligosaccharides and shunts the pathway towards hybrid-type oligosaccharides. Swainsonine does not appear to inhibit secretion or expression of glycoproteins at the cell surface. Swainsonine is stable for at least 24 h at 37oC in culture media at physiological pH. Working concentration range is 17-1700 ng/ml (0.1-10mM). Swainsonine (at 1 mg/ml) is not cytotoxic and does not inhibit the growth of a variety of mammalian cell lines. Concentrations required to inhibit Golgi a-mannosidase II in vivo may be somewhat higher, as swainsonine tends to concentrate in the acid environment of cell lysosomes, where it exists as a charged cation and does not permeate through membranes readily.Swainsonine blocks the processing of high-mannose oligosaccharides to complex oligosaccharides. Glycoproteins synthesized in the presence of swainsonine tend to carry mostly high-mannose and hybrid oligosaccharide chains. With short treatments (<24 h) with the inhibitor, cells may retain some complex glycoproteins due to asynchronous cell growth and glycoprotein synthesis.
References: J. Biol. Chem., 258, 7578-7585 (1983), Methods Enzymol., 98, 135 (1983), EMBO Journal, 3, 551-556 (1984), Mol. Cell. Biol., 5, 3467-3475 (1985), Int. J. Cancer, 44, 685 (1989),Melanoma Res., 1, 43 (1991), Bonay, P., & Fresno, M.: Glycobiology, 9(5), 423-433 (1999), Klein, J-LD, et al.: Br. J. of Cancer, 80(1/2), 87-95 (1999)